Evidence map›Paper›PMID 41550169›Full record

ReviewPharmaceutical science advances2024

Recent progresses in combination cancer therapy using cyanine dye-based nanoparticles.

Qian An, Si-Rui Xiang, You-Quan Zou

Abstract readReview
In one paragraph

Review in Pharmaceutical science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. NanoformulatedNanomaterials (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qian AnDepartment of Otolaryngology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei, 430071, China.
Si-Rui XiangDepartment of Otolaryngology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei, 430071, China.
You-Quan ZouDepartment of Otolaryngology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei, 430071, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection, radiotherapy, and chemotherapy are traditional methods for cancer treatment. With the development of materials science, photodynamic, photothermal, and sonodynamic therapies have been established over the past few years. Despite these advances, the development of novel and efficient cancer treatment protocols remains highly desirable. Recently, combination therapy has emerged as a powerful tool for achieving this goal. In this context, cyanine-nanoparticles have attracted considerable interest. Cyanine dyes have high molar absorptivity, narrow absorption/emission bands, and also excellent biocompatibility. This has meant that they have been widely used in biomedical imaging and therapy. Cyanine nanoparticles assembled from cyanine dyes and amphiphilic polymers or liposomes are endowed with high biocompatibility and long-term circulation for cancer combination therapy. A plethora of cyanine-nanoparticle-based combination therapy systems have been reported, and research in this discipline continues to expand. In this review, we aim to summarize recent advances in the combination therapy of cancers using cyanine nanoparticles over the last five years (i.e., from 2018 to 2023), with an emphasis on the structures of cyanine dyes, design concepts, and combination strategies. Personal insights and challenges in this field are also discussed. We expect that this review will inspire creative progress in combination therapies based on cyanine nanoparticles and facilitate the investigation of future clinical applications.

Indexed as

Combination therapyCyanineNanoparticlesPhotodynamic therapyPhotothermal therapy

Identifiers

PMID41550169
PMCPMC12709977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.